In one aspect, the disclosure relates to drug delivery devices for the ionophoretic delivery of a therapeutic agent(s) to the eye. In some aspects, the disclosed ionophoretic ocular delivery device is configured for delivery of a therapeutic agent to the anterior portion of the eye. In various aspects, the present disclosure provides methods for treatment of an ophthalmological disorder, disease, or clinical condition by delivering a therapeutic agent(s) to the eye using a disclosed ionophoretic ocular delivery device. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

The present embodiment comprises: an ultrasonic transducer for generating ultrasonic waves; an inner electrode having a space in which the ultrasonic transducer is accommodated; a window disposed outside the outer periphery of the inner electrode; an LED PCB disposed at the rear of the window and having an LED disposed thereon; and an outer electrode spaced apart from the inner electrode on the window, wherein the inner electrode comprises: a front body having the ultrasonic transducer disposed on the rear surface thereof; and a hollow body protruding backward from the outer periphery of the front body and having a space formed therein, wherein an inner waterproofing ring is disposed between the hollow body and the window.

Improved approaches to provide or facilitate transdermal chemical delivery to an individual are disclosed. The individual can wear an electronic transdermal chemical delivery device that delivers at least one chemical to the individual's body.

An apparatus includes multiple first reservoirs and multiple second reservoirs joined with a substrate. Selected ones of the multiple first reservoirs include a reducing agent, and first reservoir surfaces of selected ones of the multiple first reservoirs are proximate to a first substrate surface. Selected ones of the multiple second reservoirs include an oxidizing agent, and second reservoir surfaces of selected ones of the multiple second reservoirs are proximate to the first substrate surface.

A system is provided for healing a wound. The system includes a flexible body, a therapeutic agent delivery mechanism, a suction mechanism, and a power source. The flexible body includes a cover film having oppositely disposed first and second surfaces that define a compartment. The compartment includes a first porous material, a second porous material, and at least one electrode disposed therein. The second porous material is disposed between the first porous material and the at least one electrode. The therapeutic agent delivery mechanism and the suction mechanism are fluidly connected to the compartment. The power source is in electrical communication with the at least one electrode.

An active molecule delivery system whereby active molecules can be released on demand and/or a variety of different active molecules can be delivered from the same system and/or different concentrations of active molecules can be delivered from the same system. The active delivery system includes a plurality of microcells, wherein the microcells are filled with a medium for delivering the active molecules. In some embodiments the medium includes active molecules dispersed in a first charged phase as well as a second phase that is oppositely charged or uncharged and immiscible with the first phase. Where the medium includes a charged first phase, the first phase can be moved adjacent to, or away from, the porous diffusion layer in order to control the rate of delivery.

A conductive gel composition for use with a TTField-generating system is disclosed. Also disclosed are kits containing the gel composition and methods of producing and using the gel composition. The composition includes a semi-solid conductive gel for application to a patient's skin and for placement between the patient's skin and at least one transducer array that generates an alternating electric field having a frequency in a range of from about 50 kHz to about 500 kHz, wherein the conductive gel comprises a free salt present at a concentration in a range of from about 0.1 mM to about 1 M.

The present invention is directed to devices and methods that efficiently and safely kill pathogens in blood functions by the generation of metal ions in situ. Such metal ions include silver ions, copper ions, and gold ions; however, additional metals can be employed for generation of ions in situ, including platinum, iridium, and zinc. The activity of the devices and methods of the present invention is extremely broad, and can kill pathogenic bacteria, viruses, and fungi. The activity of the devices and methods of the present invention does not depend on specific interactions between the device and the surface of the pathogen being killed. Additionally, the activity of the devices and methods is not subject to the development of resistance by the pathogen, such as can occur subsequent to the administration of conventional antibacterial, antifungal, or antiviral agents.

Embodiments provide apparatus and methods for producing markings in the skin. One embodiment provides an apparatus for marking the skin comprising a housing and reservoir for storing a skin colorant. An electrode is positioned within the housing so as to be electrically coupled to the colorant in the reservoir and is configured to be coupled to a current source and return electrode. A colorant applicator having at least one fluid pathway is coupled to a housing distal end. The applicator proximal end is positioned such that the fluid pathway is coupled with the reservoir. The applicator distal end applies colorant to the skin surface through the fluid pathway as the applicator is moved across the skin. The electrode delivers current from the current source to the skin to transport charged pigment elements of the colorant into the skin using an electromotive driving force to produce a marking in the skin.

An active transdermal medicament patch includes a planar substrate with a therapeutic face releasably retainable against the skin of a patient. A return electrode and a medicament matrix susceptible to permeation by medicament are secured at separated locations on the therapeutic face and electrically conductively engage the skin. A detector monitors iontophoretic medicament migration into the skin. An integrator operating on the output of the detector produces a running cumulative total of the amount of medicament delivered during a plurality of temporally non-contiguous therapy subsessions. A circuit breaker terminates medicament migration, when the output of the integrator equals a predetermined medicament quantity. A timer active during medicament migration stimulates a driver to operate a light-emitting diode in a distinct delivery confirmation mode during each a sequence of non-overlapping predetermined therapy subsessions, respectively. A circuit board on the substrate in a compact, folded state bears interconnected electrical circuit components.